Dr. Paul Mark Bloomston, MD

Dr. Bloomston practices at South Florida Surgical Oncology in Cape Coral, Florida.

Dr. Bloomston's NPI, 1982658225, was assigned on May 20, 2006. Dr. Bloomston graduated from USF Health Morsani College of Medicine in 1997. Dr. Bloomston holds Florida license ME125024.

Dr. Bloomston's primary practice is South Florida Surgical Oncology, at 1419 SE 8th Ter, Cape Coral, FL 33990 in Lee County. The practice phone is (239) 333-0995.

Dr. Bloomston's primary practice is South Florida Surgical Oncology in Cape Coral, Florida. Dr. Bloomston is also affiliated with Cape Coral Hospital. The medical group on file is Lee Physician Group. Dmand AI also links Dr. Bloomston to 2 more hospitals, 3 group practices and clinics, 3 home health agencies and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bloomston practices, 9 sites in all. Vendor and product names are available with a free account.

Surgical oncology is Dr. Bloomston's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dr. Bloomston is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Bloomston's licenses on file in 2 states: Florida and Ohio.

CMS data shows 5,924 Medicare services from Dr. Bloomston across 11 procedure codes in 2024, for 611 Medicare patients. Medicare paid $533,980 for them.

CMS counts 611 Medicare patients who saw Dr. Bloomston in 2024. The largest group is 75 to 84, with 276 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 2.66, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bloomston's median patient age at 74, with 34% women.

In 2024, Dr. Bloomston wrote 295 Medicare Part D claims for 105 patients. 67% of them were for generic drugs. CMS names the drug for 190 of them, across 6 drugs with 11 or more claims each, at $477,114 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Bloomston for performance year 2024, reported individually. Dr. Bloomston accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bloomston as offering telehealth.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 7 papers to Dr. Bloomston, published from 2009 to 2018. 2009 was the busiest year, with 2. The most frequent topics are Liver Neoplasms and Pancreatic Neoplasms. Dr. Bloomston's most frequent co-authors are Sherif Raafat Zikry Abdel-Misih, MD, Thomas Adam Abrams, MD and Daniel H. Ahn, DO.

Dmand AI links Dr. Bloomston to 10 clinical trials, 5 of them phase 3 studies. 8 are still active or recruiting. Conditions studied include Adenocarcinoma Of Esophagus, Breast Neoplasms and Carcinoma, Non-Small-Cell Lung. National Cancer Institute (NCI) sponsors the most, 6.

CMS Open Payments shows 23 general payments to Dr. Bloomston from 8 drug and device companies from 2024 to 2025. Speaker and faculty fees make up the largest share, 75% of the total. Abbvie Inc. paid the most, $13,604.

Dmand AI lists 2 awards for Dr. Bloomston, most recently Regional Top Doctor in 2014.

Dr. Bloomston graduated from USF Health Morsani College of Medicine in 1997.

Dr. Bloomston is in network with 18 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.